November 6, 2024
On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about […]
November 5, 2024
SAN ANTONIO – Once-weekly tirzepatide (Zepbound) reduced the risk for progression from prediabetes to type 2 diabetes (T2D) by more than 90% at 3 years and […]
November 5, 2024
TOPLINE: Nearly all patients reported receiving instructions to take levothyroxine (LT4) while fasting, but a third did not adhere to this. Approximately half of patients reported […]
November 5, 2024
Editor’s note: This story has been revised to include additional comments. CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab […]
November 5, 2024
SAN ANTONIO, Texas — An upcoming document will entirely reframe obesity as a “condition of excess adiposity” that constitutes a disease called “clinical obesity” when related […]
November 5, 2024
TOPLINE: In women with polycystic ovary syndrome (PCOS) and with obesity or overweight, the combination of topiramate and metformin along with a low-calorie diet can result […]
November 4, 2024
LONDON (Reuters) -AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China’s Eccogene for up to $2 billion, was safe and tolerable […]
November 4, 2024
SAN ANTONIO — Treatment with once-weekly semaglutide 2.4 mg (Wegovy) significantly reduced hospital admissions for all causes — not just cardiac — and overall hospitalization time […]
November 4, 2024
CHICAGO — The investigational monoclonal antibody batoclimab showed safety and rapid and significant improvement in key markers of Graves’ disease, with some patients who failed to […]